|Dr. Luca Santarelli M.D.||Founder, CEO & Director||N/A||N/A||1969|
|Ms. Claudia D'Augusta Ph.D.||Chief Financial Officer||N/A||N/A||1970|
|Dr. Christian Meyer M.D., Ph.D.||Chief Operating Officer||N/A||N/A||1967|
|Dr. Alain Bernard Ph.D.||Chief Technology Officer||N/A||N/A||1957|
|Mr. Patrick Malloy||Sr. VP of Investor Relations & Strategic Communications||N/A||N/A||N/A|
|Mr. Scott Applebaum||Chief Legal Officer & Corp. Sec.||N/A||N/A||1967|
|Mr. Kevin Harris||Chief Commercial Officer||N/A||N/A||1971|
|Dr. Sarah Holland Ph.D.||Chief Bus. Officer||N/A||N/A||1963|
|Dr. Omar Khwaja M.D., Ph.D.||Chief Medical Officer||N/A||N/A||1971|
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.
VectivBio Holding AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.